Dexcom adds enhanced smart meal logging feature to Stelo CGM
February 4, 2026
Dexcom (NSDQ:DXCM) announced today that it plans to launch an advanced AI-enabled enhancement to its Stelo over-the-counter CGM.
Dexcom (NSDQ:DXCM) announced today that it plans to launch an advanced AI-enabled enhancement to its Stelo over-the-counter CGM.
Quest expects the new blood test will support response monitoring in clinical trials.
ORANGEBURG, S.C., Jan. 29, 2026 /PRNewswire/ — Zeus, a global leader in advanced polymer solutions, today announced the launch of PFX™, a breakthrough platform designed to advance catheter innovation with a focus on performance, design flexibility, and sustainability.
From M&A to surgical robotics and user fee negotiations, the medical device industry has a busy year ahead. Check out MedTech Dive’s roundup of the top medtech trends to watch in 2026.
Imperative Care announced the launch of the new Zoom 4S thrombectomy catheter and reported the first patient cases with the device.
Olympus today announced the U.S. launch of its most advanced single-use fine needle biopsy device.
“The Maestro combines advanced functionality with more sustainable design and electronic integration, making it ideal for today’s clinical and home healthcare applications,” said Eric Saks.
RAMAT GAN, Israel, Jan. 26, 2026 /PRNewswire/ — Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a global leader in connected home ultrasound technology, today announced an additional strategic commercial agreement with Clalit Health Services, Israel’s largest health maintenance organization (HMO), to supply Pulsenmore FC, a new at-home ultrasound solution designed for remote follicular monitoring in women undergoing fertility care (IVF and fertility preservation).
Penumbra (NYSE:PEN) announced today that it launched the Lightning Flash 3.0 computer-assisted vacuum thrombectomy (CAVT) system.
BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ — Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration’s recent clarification regarding non-medical-grade wearable devices, noting that the FDA’s position establishes a regulatory framework highly conducive to Woori IO’s commercialization strategy.